We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+26.89%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$233M
AUM Growth
+$19M
(+8.9%)
Cap. Flow
-$54.1M
Cap. Flow
% of AUM
-23.21%
Top 10 Holdings %
Top 10 Hldgs %
51.27%
Holding
65
New
21
Increased
9
Reduced
22
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$7.06M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
+$5.61M |
| 3 |
CLLS
Cellectis
CLLS
|
+$4.21M |
| 4 |
Baxter International
BAX
|
+$3.7M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$3.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$11.1M |
| 2 |
Kura Oncology
KURA
|
+$11M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$10.6M |
| 4 |
United Therapeutics
UTHR
|
+$8.89M |
| 5 |
Direxion Daily Small Cap Bear 3x ETF
TZA
|
+$7.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.12% |
| 2 | Miscellaneous | 13.55% |
| 3 | Technology | 3.99% |
| 4 | Energy | 0.34% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZGNX
51
PUT
DELISTED
Zogenix, Inc.
ZGNX
| $221K | 0.09% |
+8,200
| New | +$226K |
|
52
CALL
Evolus
EOLS
$587M
| $198K | 0.09% |
37,400
-36,300
| -49% | -$167K |
|
53
AbbVie
ABBV
$451B
| – | – |
-16,030
| Closed | -$1.22M |
|
54
AnaptysBio
ANAB
$1.67B
| – | – |
-78,976
| Closed | -$1.12M |
|
55
BioMarin Pharmaceuticals
BMRN
$12.5B
| – | – |
-22,900
| Closed | -$1.94M |
|
56
HCA Healthcare
HCA
$90.5B
| – | – |
-9,223
| Closed | -$829K |
|
|
KZR
57
DELISTED
Kezar Life Sciences
KZR
| – | – |
-9,662
| Closed | -$421K |
|
58
Ligand Pharmaceuticals
LGND
$5.59B
| – | – |
-18,435
| Closed | -$836K |
|
59
Milestone Pharmaceuticals
MIST
$144M
| – | – |
-41,592
| Closed | -$77K |
|
60
Insperity
NSP
$2.04B
| – | – |
-12,900
| Closed | -$481K |
|
61
Envista
NVST
$4.36B
| – | – |
-58,000
| Closed | -$867K |
|
62
Tenet Healthcare
THC
$21.5B
| – | – |
-20,918
| Closed | -$301K |
|
|
63
Direxion Daily Small Cap Bear 3x ETF
TZA
$251M
| – | – |
-1,563
| Closed | -$7.42M |
|
64
UroGen Pharma
URGN
$2.13B
| – | – |
-146,179
| Closed | -$2.61M |
|
|
CHNG
65
CALL
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| – | – |
-100,000
| Closed | -$999K |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q2 2020 Portfolio in Review
As of Q2 2020, Prosight Management held 65 positions worth $233M, up 8.9% from $214M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Prosight Management withdrew a net $54.1M in Q2 2020, closing 13 positions and reducing 22 holdings. Its most notable exit was Direxion Daily Small Cap Bear 3x ETF, an estimated $7.42M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Prosight Management opened a new position in Bristol-Myers Squibb worth $6.94M.
- Prosight Management's largest Q2 2020 buy was Bristol-Myers Squibb: 118,000 shares worth $6.94M.
- Prosight Management added most to Change Healthcare Inc. Common Stock in Q2 2020, an estimated $3.04M increase.
- Prosight Management's biggest Q2 2020 reduction was Iovance Biotherapeutics, cutting an estimated $11.1M.
- Prosight Management fully exited Direxion Daily Small Cap Bear 3x ETF in Q2 2020, selling an estimated $7.42M.
- Prosight Management's ten largest holdings make up 51% of its $233M portfolio in Q2 2020.
- Prosight Management opened 21 new positions and closed 13 in Q2 2020.
- Prosight Management's portfolio value rose 8.9% quarter-over-quarter to $233M.
Based on Prosight Management's 13F filing for Q2 2020, filed 14 Aug 2020.